The online version of this article (doi:10.1186/s40035-017-0079-3) contains supplementary material, which is available to authorized users.
The hereditary spastic paraplegias (HSPs) are a group of clinically and genetically heterogeneous disorders. Approximately 10% of the autosomal dominant (AD) HSPs (ADHSPs) have the spastic paraplegia 3A (SPG3A) genotype which is caused by ATL1 gene mutations. Currently there are more than 60 reported ATL1 gene mutations and the genotype-phenotype correlation remains unclear. The study aims to investigate the genotype-phenotype correlation in SPG3A patients.
We performed a reanalysis of the clinical features and genotype-phenotype correlations in 51 reported studies exhibiting an ATL1 gene mutation.
Most HSPs-SPG3A patients exhibited an early age at onset (AAO) of <10 years old, and showed an autosomal dominant pure spastic paraplegia. We found that 14% of the HSPs-SPG3A patients presented complicated phenotypes, with distal atrophy being the most common complicated symptom. The AAO of each mutation group was not statistically significant (P > 0.05). The mutational spectrum associated with ATL1 gene mutation is wide, and most mutations are missense mutations, but do not involve the functional motif of ATL1 gene encoded atlastin-1 protein.
Our findings indicate that there is no clear genotype-phenotype correlation in HSPs-SPG3A patients. We also find that exons 4, 7, 8 and 12 are mutation hotspots in ATL1 gene.
Additional file 1: Table S1. Correlation between clinical and genetic characteristics in patients with mutant ATL1. (DOC 562 kb)40035_2017_79_MOESM1_ESM.doc
Mc Dermott CJ, et al. Hereditary spastic paraparesis: a review of new developments. J Neurol Neurosurg Psychiatry. 2000;69(2):150–60. CrossRef
Tallaksen CM, Durr A, Brice A. Recent advances in hereditary spastic paraplegia. Current Opinion Neurol. 2001;14:457–63. CrossRef
Rainier S, et al. De novo occurrence of novel SPG3A/atlastin mutation presenting as cerebral palsy. Arch Neurol. 2005;63(3):445–7. CrossRef
Chen SQ, et al. Severe hereditary spastic paraplegia caused by a de novo SPG3A mutation. Sci China. 2005;51(15):1854–6. In Chinese.
Matsui M, et al. A novel mutation in the SPG3A gene (atlastin) in hereditary spastic paraplegia. J Neurol. 2007;54(7):972–4. CrossRef
Li XH, et al. A SPG3A mutation with a novel foot phenotype of hereditary spastic paraplegia in a Chinese Han family. Chin Med J (Engl). 2007;120(9):834–7.
Ming L. SPG3A-hereditary spastin paraplegia with genetic anticipation and incomplete penetrance. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2007;24(1):15–8. In Chinese. PubMed
Chan KY, et al. Hereditary spastic paraplegia: identification of an SPG3A gene mutation in a Chinese family. Hong Kong Med J. 2009;15(4):304–7. PubMed
Kwon MJ, et al. Clinical and genetic analysis of a Korean family with hereditary spastic paraplegia type 3. Ann Clin Lab Sci. 2010;40(4):375–9. PubMed
Sulek A, et al. Screening for the hereditary spastic paraplaegias SPG4 and SPG3A with the multiplex ligation-dependent probe amplification technique in a large population of affected individuals. Neurol Sci. 2012;34(2):239–42. CrossRef
Namekawa M, et al. A founder effect and mutational hotpots may contribute to the most frequent mutations in the SPG3A gene. Neurogenetics. 2016;7(2):131–2. CrossRef
- Clinical features and genotype-phenotype correlation analysis in patients with ATL1 mutations: A literature reanalysis
- BioMed Central